Search research articles
Contact Us
Filters
Showing results (11-20 of 56) with videos related to
Page
of 6
Sort By:
Journal of Mass Spectrometry : JMS
|
August 9, 2007
Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study
M Wade Calcutt, Wooin Lee, Igor Puzanov, et al.
Molecular Pharmacology
|
August 24, 2004
Induction of radiosensitization by indolocarbazole derivatives: the role of DNA topoisomerase I
Allan Y Chen, Shyh-Jen Shih, Michael Hsiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2006
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer
Maurie Markman, P Y Liu, Mace L Rothenberg, et al.
Molecular Cancer Therapeutics
|
February 17, 2005
Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer
Allan Y Chen, Shyh-Jen Shih, Liza N Garriques, et al.
American Journal of Clinical Oncology
|
October 8, 2008
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies
Laura W Goff, Mace L Rothenberg, A Craig Lockhart, et al.
Biologics : Targets & Therapy
|
August 27, 2009
Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases
Peter J O'Brien, Rajeev Ramanathan, Jonathan M Yingling, et al.
Head & Neck
|
July 24, 2010
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma
Christine H Chung, Paula R Pohlmann, Mace L Rothenberg, et al.
Investigational New Drugs
|
August 11, 2010
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors
Andrea Wang-Gillam, Susanne M Arnold, Ronald M Bukowski, et al.
American Journal of Clinical Oncology
|
February 6, 2009
A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors
A Craig Lockhart, Emiliano Calvo, Anthony W Tolcher, et al.
American Journal of Clinical Oncology
|
January 11, 2011
Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer
Emily Chan, Bonnie Lafleur, Mace L Rothenberg, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 56) with videos related to
Sort By:
Page
of 6
Journal of Mass Spectrometry : JMS
|
August 9, 2007
Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study
M Wade Calcutt, Wooin Lee, Igor Puzanov, et al.
Molecular Pharmacology
|
August 24, 2004
Induction of radiosensitization by indolocarbazole derivatives: the role of DNA topoisomerase I
Allan Y Chen, Shyh-Jen Shih, Michael Hsiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2006
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer
Maurie Markman, P Y Liu, Mace L Rothenberg, et al.
Molecular Cancer Therapeutics
|
February 17, 2005
Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer
Allan Y Chen, Shyh-Jen Shih, Liza N Garriques, et al.
American Journal of Clinical Oncology
|
October 8, 2008
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies
Laura W Goff, Mace L Rothenberg, A Craig Lockhart, et al.
Biologics : Targets & Therapy
|
August 27, 2009
Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases
Peter J O'Brien, Rajeev Ramanathan, Jonathan M Yingling, et al.
Head & Neck
|
July 24, 2010
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma
Christine H Chung, Paula R Pohlmann, Mace L Rothenberg, et al.
Investigational New Drugs
|
August 11, 2010
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors
Andrea Wang-Gillam, Susanne M Arnold, Ronald M Bukowski, et al.
American Journal of Clinical Oncology
|
February 6, 2009
A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors
A Craig Lockhart, Emiliano Calvo, Anthony W Tolcher, et al.
American Journal of Clinical Oncology
|
January 11, 2011
Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer
Emily Chan, Bonnie Lafleur, Mace L Rothenberg, et al.
Page
of 6